COSMOS Pharmaceutical Corporation (3349.T)

Worse than 3088.T's revenue growth rate of 31.08%.

Worse than 3088.T's ebitda of 56.27B.

Worse than 3088.T's ebitda margin of 7.71%.

Worse than 3088.T's ebit of 41.41B.

Worse than 3088.T's ebit margin of 5.67%.

Worse than 3088.T's depreciation of 14.86B.

Worse than 3088.T's total cash of 74.52B.

Worse than 3088.T's cash as percentage of revenue of 10.21%.

Worse than 3088.T's accounts payable of 92.50B.

Worse than 3088.T's payables as percentage of revenue of 12.67%.

Worse than 3088.T's weighted average cost of capital (wacc) of 4.93%.

Worse than 3088.T's cost of equity of 4.93%.

Worse than 3088.T's beta of 0.17.

Worse than 3088.T's total debt of 2.21B.

Worse than 3088.T's total equity of 1.17T.

Worse than 3088.T's total capital of 1.17T.

Worse than 3088.T's debt weighting of 0.19%.

Worse than 3088.T's equity weighting of 99.81%.

Worse than 3088.T's ebiat of 28.68B.

Worse than 3088.T's long-term growth rate of 3.00%.

Worse than 3088.T's terminal value of 2.82T.

Worse than 3088.T's enterprise value of 2.45T.

Worse than 3088.T's net debt of -109.55B.

Worse than 3088.T's equity value of 2.56T.

Worse than 3088.T's equity value per share of 6262.42.